Deregulation of Protein Phosphatase 2A Inhibitor SET Is Associated with Malignant Progression in Breast Cancer

SET, an endogenous inhibitor of protein phosphatase 2A, was overexpressed in all subtypes of invasive breast carcinoma tissues. Treatment with SET-targeted siRNAs reduced the motility of MCF-7 and MDA-MB-231 cells in transwell assay.